T. Rowe Price Associates
BCLI

T. Rowe Price Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

T. Rowe Price Associates’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,780
Closed -$9K – 2908
2023
Q3 		$9K Sell
2,780
-1,700
-38% -$38.7K ﹤0.01% 2870
2023
Q2 		$139K Sell
4,480
-2,720
-38% -$113K ﹤0.01% 2626
2023
Q1 		$357K Hold
7,200
– – ﹤0.01% 2262
2022
Q4 		$177K Hold
7,200
– – ﹤0.01% 2571
2022
Q3 		$478K Buy
7,200
+1,000
+16% +$50.2K ﹤0.01% 2148
2022
Q2 		$257K Hold
6,200
– – ﹤0.01% 2506
2022
Q1 		$312K Hold
6,200
– – ﹤0.01% 2537
2021
Q4 		$372K Hold
6,200
– – ﹤0.01% 2518
2021
Q3 		$307K Hold
6,200
– – ﹤0.01% 2570
2021
Q2 		$353K Sell
6,200
-1,944
-24% -$104K ﹤0.01% 2531
2021
Q1 		$468K Buy
8,144
+6,690
+460% +$505K ﹤0.01% 2402
2020
Q4 		$99K Buy
1,454
+753
+107% +$103K ﹤0.01% 2626
2020
Q3 		$178K Buy
+701
New +$144K ﹤0.01% 2443

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

T. Rowe Price Associates's BCLI Position: Q4 2023 in Review

T. Rowe Price Associates sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 2,780 shares — an estimated $9K sold.

T. Rowe Price Associates first reported a position in BCLI in Q3 2020 and held it in 13 quarters. The position peaked at $478K in Q3 2022. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • T. Rowe Price Associates reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,780 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $9K.
  • T. Rowe Price Associates first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2020 and held it in 13 quarters.
  • T. Rowe Price Associates's BRAINSTORM CELL THERAPUTC position peaked at $478K in Q3 2022.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.